Advocate Aurora launches venture with Foxconn to transform care delivery

Advocate Aurora Health and Foxconn Health Technology Business Group have launched a collaborative venture to enhance employee wellness, build a smart city infrastructure and invest in transformational care.

The collaboration comes just months after Illinois-based Advocate Health Care closed its merger with Milwaukee-based Aurora Health Care to form Advocate Aurora Health. The combined company is the nation’s 10th largest not-for-profit health system.  

The venture is also part of Foxconn’s previously announced plan to build a $10 billion plant in Racine County, Wisconsin.

"Technology will play a critical role in the future of health and wellness," Nick Turkal, MD, Advocate Aurora Health president and CEO, said in a statement. "We are excited about what we can do together to benefit not only our patients and communities here locally, but how our combined capabilities could potentially have a positive impact on wellness globally."

Within its employer-based solution focus area, the companies plan to leverage predictive modeling and artificial intelligence as well as population health management to improve employer healthcare cost forecasting and wellness programs.

The partnership will also create a smart city concept that aims to link consumer health, fitness and dietary data across home, work, mobile, community and clinical environments. The concept will create a digital network connecting healthcare entities outside the hospital environment, including nursing homes, pharmacies, ambulances and federally qualified health centers, and lower overall care costs.

"We are pleased to establish this robust partnership with Advocate Aurora Health with our technology portfolio," Leonard Wu, CEO of Foxconn Health Technology Business Group, said in a statement. "We have utilized some of these same technologies with our own employees and are pleased to adopt them here to enhance health from the workplace to the community."

The companies also plan to invest in emerging medical disciplines, such as precision medicine and genomics, and recruitment and training initiatives.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.